Table 2.
Antiviral activity and cytotoxicity of ALG-097111, and remdesivir in various cell-based antiviral assays.
| SARS-CoV-2Nluc (A549)a |
β-CoV OC43 (HeLa) |
α-CoV 229E (Huh-7) |
||||
|---|---|---|---|---|---|---|
| EC50 [nM] | CC50 [nM] | EC50 [nM] | CC50 [nM] | EC50 [nM] | CC50 [nM] | |
| ALG-097111 | 200 ± 18.4 (n = 2) | >100 000 | 123.3 ± 21.1 (n = 4) | >100 000 | 366.5 ± 199.1 (n = 2) | >25 000 |
| Remdesivir | 31.6 ± 11.9 (n = 2) | >50 000 | 102.4 ± 50.53 (n = 46) | >5000 | 14.47 ± 3.48 (n = 18) | >1000 |
a
The SARS-CoV-2-Nluc antiviral assay was performed using A549-hACE2 cells while the cytotoxicity was performed in A549 cells.